MEDICINE • RANDOMIZED PHASE 3 TRIALS • OCTOBER 26, 2026
Two Cancer Therapies Extend Survival in Major Human Trials
Evidence level: Randomized Phase 3 survival outcomes in defined patient populations. Neither therapy is a general anti-aging intervention; both remain investigational for the uses discussed.
1. Divarasib for KRAS G12C-mutated lung cancer
The Krascendo 1 randomized trial studied 338 adults with previously treated advanced non-small-cell lung cancer carrying the KRAS G12C mutation. Investigational divarasib was compared with approved KRAS G12C inhibitors sotorasib or adagrasib.
| Outcome | Divarasib | Comparator |
|---|---|---|
| Median overall survival | 17.7 months | 12.0 months |
| Median progression-free survival | 9.8 months | 5.7 months |
| Objective response rate | 58% | 32% |
Overall survival hazard ratio: 0.56 (95% CI 0.41–0.78). Serious treatment-related adverse events were reported in 7.8% versus 15.2%, respectively. These are group-level outcomes and cannot predict individual survival.
2. Sonesitatug vedotin for CLDN18.2-positive gastrointestinal cancer
The randomized CLARITY-Gastric01 trial enrolled 532 people with previously treated advanced gastric, gastroesophageal-junction or esophageal adenocarcinoma expressing CLDN18.2. Sonesitatug vedotin is an investigational antibody-drug conjugate carrying a cytotoxic payload to CLDN18.2-expressing tumor cells.
| Outcome | Sonesitatug vedotin | Investigator's choice |
|---|---|---|
| Median overall survival, third line or later | 10.0 months | 5.0 months |
| 12-month survival, third line or later | 38.1% | 18.1% |
| Median overall survival, full second-line-or-later group | 10.6 months | 6.4 months |
The third-line-or-later overall-survival hazard ratio was 0.47 (95% CI 0.36–0.62). The trial did not meet its other dual primary endpoint: centrally assessed progression-free survival in the overall population (reported p=0.053). Grade 3 or higher treatment-related adverse events occurred in 36.4% with sonesitatug vedotin and 44.8% with investigator's choice; gastrointestinal side effects remained important. As of October 26, detailed results were available from a conference presentation and sponsor reporting rather than a complete peer-reviewed publication.
Why these studies matter for healthspan
Unlike laboratory biomarkers or animal lifespan results, these trials measure actual survival in people. They may offer eligible patients more time alive following serious illness. They do not show that biological aging slows, healthy people live longer, or immune systems are generally rejuvenated. Trial populations, adverse effects, access and regulatory status all matter.
Primary and supporting sources
New England Journal of Medicine: Krascendo 1 (2026)
Roche: detailed Krascendo 1 data
AstraZeneca: CLARITY-Gastric01 results and safety
Educational research summary, not medical advice. Published October 26, 2026.
Related research
Explore connected evidence and questions across the Murphy Knowledge Project.